Allos Therapeutics, Inc. (NASDAQ: ALTH), a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics, today announced that the Company will report its financial results for the fourth quarter and full year ended December 31, 2011 on Tuesday, March 6, 2012, after the financial markets close. Following the release of the financial results, Allos management will provide a corporate update via conference call and audio webcast. Access to the conference call and webcast may be obtained as follows:
Time: 4:30 PM ET / 2:30 PM MT
Date: Tuesday, March 6, 2012
Dial-in: 1-877-941-0843 (U.S.) or +480-629-9819 (Canada and international)
(homepage and “Investors - Presentations and Events” section)
A recorded rebroadcast will be available for interested parties unable to attend the live conference call by dialing 1-800-406-7325 (domestic) or +1-303-590-3030 (international) and using passcode 4515372#. Webcast and telephone replays of the conference call will be available approximately two hours after the completion of the call through March 20, 2012.
About Allos Therapeutics
Allos Therapeutics, Inc. (Nasdaq: ALTH) is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. Allos is currently focused on the development and commercialization of FOLOTYN
(pralatrexate injection), a folate analogue metabolic inhibitor. FOLOTYN is approved in the U.S. for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma, or PTCL. For additional information, please visit
Safe Harbor Statement
The anticipated presentation will contain forward-looking statements that involve significant risks and uncertainties. Additional information concerning these forward-looking statements and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2011 and in the Company's other periodic reports and filings with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained in the presentation. All forward-looking statements are based on information currently available to the Company on the date thereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of these presentations, except as required by law.